Skip to main content

LCD L39935: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

LCD L39935, MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2025-08-17. The policy text runs 274 words, and its billing and coding article A59849 lists 19 ICD-10-CM codes that support medical necessity for 2 procedure codes. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 19 covered ICD-10-CM codes: the same total as L39940 (CGS Administrators, LLC, 19 codes, revised 2026-03-19) and the same total as L39948 (Noridian Healthcare Solutions, LLC, 19 codes, revised 2026-02-05).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2025-08-17
Original effective
2025-08-17
Policy text
274 words
Covered ICD-10 codes (articles)
19

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39935
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A59849: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59849 (Billing and Coding: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A59849: Billing and Coding: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (Billing and Coding, effective 2026-10-01)

Covered ICD-10-CM codes
19
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
2
Full article
cms.gov record
First 19 covered ICD-10-CM codes in A59849
ICD-10-CMDescription (FY2027)
E85.0Non-neuropathic heredofamilial amyloidosis
E85.1Neuropathic heredofamilial amyloidosis
E85.2Heredofamilial amyloidosis, unspecified
E85.3Secondary systemic amyloidosis
E85.4Organ-limited amyloidosis
G57.90Unspecified mononeuropathy of unspecified lower limb
G57.91Unspecified mononeuropathy of right lower limb
G57.92Unspecified mononeuropathy of left lower limb
G57.93Unspecified mononeuropathy of bilateral lower limbs
G59Mononeuropathy in diseases classified elsewhere
G60.3Idiopathic progressive neuropathy
G60.9Hereditary and idiopathic neuropathy, unspecified
I42.01Familial-genetic dilated cardiomyopathy
I42.09Other dilated cardiomyopathy
I42.1Obstructive hypertrophic cardiomyopathy
I42.2Other hypertrophic cardiomyopathy
I42.81Arrhythmogenic cardiomyopathy
I42.89Other cardiomyopathies not elsewhere classified
I43Cardiomyopathy in diseases classified elsewhere

Procedure codes: 81404, 81479.

Coverage indications, limitations and medical necessity

This contractor will cover molecular diagnostic tests for use in the evaluation and management of beneficiaries suspected of having Hereditary Transthyretin Amyloidosis (hATTR) when all the following criteria are met:

• The patient has a clinical diagnosis of ATTR; OR

• Has cardiac features suggestive of ATTR-cardiomyopathy; AND

• Is of African ancestry; OR

• Has a first-degree relative with an hATTR diagnosis; OR

• Has at least one additional feature suggestive of hATTR according to expert consensus and society guidelines.

• Has progressive sensorimotor and/or autonomic neuropathy; AND

• Has a first-degree relative with an hATTR diagnosis; OR

• Has at least one additional features suggestive of hATTR according to expert consensus and society guidelines.

• The patient has been offered counseling regarding the test and potential results.

• The results of the test will be used to aid in treatment decisions.

• The test performed includes at least the minimum genetic content (genes or genetic variants) with definitive or well-established guidelines-based evidence required for clinical decision making for its intended use that can be reasonably detected by the test.

• The test does not include additional genetic content that is not properly validated, or of unclear clinical validity or utility such that it could reasonably or possibly be mis-utilized by the patient or treating physician and result in impaired patient outcomes.

• A single variant may be tested if it is the only variant considered to be reasonable and necessary for a patient given that it is a known familial variant.

• The test has successfully completed a technical assessment (TA) that ensures the test is reasonable and necessary as described above.

Summary of evidence (opening)

Background

Transthyretin is a protein produced in the liver, choroid plexus, and retinal pigment epithelium and transports thyroid hormone thyroxine and the retinal-binding protein bound to retinol. 1,2 In transthyretin amyloidosis (ATTR) the homotetrameric protein is destabilized, leading to monomers that misfold, aggregate and form amyloid fibrils. These fibrils are deposited in certain organs including the heart, eyes, digestive tract, nervous system, and kidneys. 3 There are two types of ATTR: a sporadic, non-genetic form known as wild-type ATTR (wtATTR) and a hereditary form (hATTR, also referred to as the variant form ATTRv) caused by pathogenic variants in the TTR gene inherited in an autosomal dominant (AD) manner. In patients with wtATTR, amyloid fibrils are deposited almost entirely in the myocardium, resulting in ATTR cardiomyopathy (ATTR-CM). 4,5 In contrast, hATTR may present as ATTR-CM, polyneuropathy (ATTR-PN), or a mixed phenotype of both through the deposition of the misfolded protein in both the cardiovascular and peripheral nervous systems. 3,6 The true prevalence of wtATTR is unknown; however autopsy studies have suggested that it is higher than previously recognized with some studies showing that ~25% of individuals 80 or older have wild-type fibrils, regardless of symptoms. 5,7-9 Historically, hATTR was thought to be endemic to certain regions including northern Portugal, northern Sweden and Japan with a prevalence of 1-10 per 10,000 individuals. However, to date the disorder has now been reported in multiple countries with an estimated global prevalence of 5000-40,000 individuals. 9-11

Diagnosis

Symptoms of patients with ATTR-CM include those commonly seen in heart failure including fatigue, exercise intolerance, palpitations, conduction abnormalities, and arrhythmias. 4,5 Other early indicator disease characteristics include elevated troponin or N-terminal pro-brain natriuretic peptide levels, an intolerance of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or beta-blockers, carpel tunnel syndrome (CTS), lumbar spinal stenosis, and biceps tendon rupture. 4,12,13 The age of onset of wtATTR-CM is generally above the age of 60, whereas that of hATTR-CM varies from 30-80 years old depending on the TTR variant. The median survival after diagnosis is ~3.5 and ~2.5 years respectively for wtATTR-CM and hATTR-CM. 4 The clinical presentation of patients with hATTR-PN is also variable with no specific signs or symptoms uniquely associated with the disease. However, a number of “red flags” have been identified that should raise suspicion. 14 Karam et al. reported that the most important features suggestive of hATTR are the rate of neuropathy progression and comorbidities such as gastrointestinal dysmotility, heart failure with preserved ejection fraction, autonomic failure and CTS. 15 For example, although common in the general population, CTS in patients with hATTR is more often bilateral, more prone to recurrence and more refractory to treatment. A family or personal history of idiopathic neuropathy that does not respond to treatments for other neuropathies or is rapidly progressing is also suggestive for hATTR.

The contractor cites 53 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2025-08-17
Current revision effective
2025-08-17
Last reviewed by the contractor
2025-06-23
MCD version
8

Other related documents: A60190 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39935 cover?

• Has at least one additional features suggestive of hATTR according to expert consensus and society guidelines. The full 274-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39935 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39935?

The companion billing and coding article A59849 lists 19 ICD-10-CM codes in 1 group that support medical necessity; the first 19 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39935?

A denial under LCD L39935 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59849's 19 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.